Advanced in Juvenile Idiopathic Arthritis (JIA)

Dr. Geoffrey S. Gladstein

Rheumatology
5520 Park Ave, 
Trumbull, CT 
Advanced in Juvenile Idiopathic Arthritis (JIA)
5520 Park Ave, 
Trumbull, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Geoffrey Gladstein is a Rheumatologist in Trumbull, Connecticut. Dr. Gladstein is rated as an Advanced provider by MediFind in the treatment of Juvenile Idiopathic Arthritis (JIA). His top areas of expertise are Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Arthritis, and Axial Spondyloarthritis (AxSpA).

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Specialist in CT
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

5520 Park Ave, Trumbull, CT 06611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: November 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

2 Total Publications

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).
Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).
Journal: Annals of the rheumatic diseases
Published: September 16, 2011
Similar Doctors
Elite in Juvenile Idiopathic Arthritis (JIA)
Dr. Karen B. Onel
Pediatric Rheumatology | Rheumatology
Elite in Juvenile Idiopathic Arthritis (JIA)
Dr. Karen B. Onel
Pediatric Rheumatology | Rheumatology
535 E 70th St, 
New York, NY 
 (48.9 miles away)
212-606-1302
Languages Spoken:
English
See accepted insurances

Karen Onel is a Pediatric Rheumatologist and a Rheumatologist in New York, New York. Dr. Onel is rated as a Distinguished provider by MediFind in the treatment of Juvenile Idiopathic Arthritis (JIA). Her top areas of expertise are Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE), Arthritis, and Lupus Nephritis.

Advanced in Juvenile Idiopathic Arthritis (JIA)
Dr. Lisa A. Mandl
Rheumatology
Advanced in Juvenile Idiopathic Arthritis (JIA)
Dr. Lisa A. Mandl
Rheumatology

New York Society For The Relief Of Ruptured And Crippled Maintaining

535 E 70th St, 
New York, NY 
 (48.9 miles away)
212-774-7598
Languages Spoken:
English
See accepted insurances

Lisa Mandl is a Rheumatologist in New York, New York. Dr. Mandl is rated as a Distinguished provider by MediFind in the treatment of Juvenile Idiopathic Arthritis (JIA). Her top areas of expertise are Arthritis, Systemic Lupus Erythematosus (SLE), Psoriatic Arthritis, Knee Replacement, and Hip Replacement.

Advanced in Juvenile Idiopathic Arthritis (JIA)
Dr. Lisa F. Imundo
Pediatric Rheumatology | Pediatrics | Rheumatology
Advanced in Juvenile Idiopathic Arthritis (JIA)
Dr. Lisa F. Imundo
Pediatric Rheumatology | Pediatrics | Rheumatology

Trustees Of Columbia University In The City Of New York

161 Fort Washington Ave, 
New York, NY 
 (45.2 miles away)
212-305-3870
Languages Spoken:
English
See accepted insurances

Lisa Imundo is a Pediatric Rheumatologist and a Pediatrics provider in New York, New York. Dr. Imundo is rated as an Advanced provider by MediFind in the treatment of Juvenile Idiopathic Arthritis (JIA). Her top areas of expertise are Systemic Lupus Erythematosus (SLE), Juvenile Idiopathic Arthritis (JIA), Vasculitis, Polyarteritis Nodosa, and Tissue Biopsy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gladstein's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile